Five Prime Announces Fourth Quarter and Full Year 2015 Financial Results
March 10, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10
February 26, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel...
Five Prime Therapeutics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
February 04, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and...
Five Prime Therapeutics Announces Key Executive Appointments
February 01, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
Kevin Baker, Ph.D., appointed as Senior Vice President of Development SciencesRobert Sikorski, M.D., Ph.D., promoted to Senior Vice President of Global Clinical Development SOUTH SAN FRANCISCO,...
Five Prime Therapeutics Announces Preliminary Data From the Dose Escalation Portion of the Phase 1 Trial of FPA144 at the ASCO GI Cancers Symposium
January 21, 2016 15:00 ET
|
Five Prime Therapeutics, Inc.
Preliminary data on anti-tumor activity, including two partial responses in six gastric cancer patients whose tumors overexpress the FGFR2b proteinFPA144 was well tolerated and differentiated from...
Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis (PVNS)
January 13, 2016 09:15 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
Five Prime Therapeutics Provides Update on FP-1039 Clinical Program
January 11, 2016 04:00 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel...
Five Prime Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
January 06, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and...
Five Prime Therapeutics Appoints Prominent Immuno-Oncology Thought Leaders to Scientific Advisory Board
January 05, 2016 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel...
Five Prime Therapeutics Appoints Drug Development Leaders to Board of Directors
December 03, 2015 16:05 ET
|
Five Prime Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein...